European Month of the Brain: Calling Attention to the Troubled State of Brain Research
Crisis is one word that has been used to describe the current state of research and development in the field of brain-related disorders.
IMI
World Immunization Week: Immunization Campaigns Face Unique Hurdles
You can’t provide a person with a routine, potentially life-saving, vaccine if you can’t find them. This is the point driven home by a recent Nature article, which suggests that the difficulty of vaccinating Nigerian nomads could be among the final hurdles to polio eradication. To address this, the National Stop Transmission of Polio (N-STOP) programme has undertaken a census of Fulani nomads and other isolated populations in Nigeria.
Finding Solutions in Public-Private Partnerships: Japanese Pharma Joins the Trend
Public-private partnerships in the world of medicines development offer a unique opportunity to power innovation forward. By pooling the resources of diverse stakeholders – from governments to the pharmaceutical industry, academic institutions and more – PPPs have the potential to tackle today’s toughest healthcare challenges.
SRA PUBLIC CONSULTATION
Call for input contribution to the consultation paper on IMI2 strategic research agenda - deadline for input 30 April 2013.
New Drugs for 4 Bad Bugs
IMI Launches Antimicrobial resistance (AMR) projects to revitalise antibiotic development
Brussels, 11 February 2013 -Today the Innovative Medicines Initiative (link) will launch two new projects through its antimicrobial resistance programme New Drugs for Bad Bugs (ND4BB). Both projects- COMBACTE (Combatting Bacterial Resistance in Europe) and TRANSLOCATION (Molecular basis of the bacterial cell wall permeability) will seek to tackle the growing problem of antimicrobial resistance throughout the EU that is currently the cause of over 25000 deaths in the EU every year and cost the European economy over 1.5billion euro a year.
European Parliament calls for immediate action to tackle antimicrobial resistance
Cuts, Cuts, Cuts!-But what about innovation?
EFPIAs Director General Richard Bergström puts forward his views on the hot topic of the EU budget and the importance of preserving innovation.
Clinical Trials
Introduction
A clinical trial is a research study conducted in human participants to evaluate the safety and efficacy of a medicine expected to improve patients health. Clinical trials can only be started after a compound has survived rigorous pre-clinical development work, which involves laboratory testing (chemical/biological/pharmacological/toxicological). It is only when these tests show favourable and promising results that a company can proceed to assess the medicine in humans.
European Health Forum Gastein 2012
This year in Gatsein, EFPIA was present on two workshops:
- Together with IMI we presented new ways of doing research explaining how opening collaboration to new actors was the favoured way forward today by every researcher and industry. New collaboration is a tremendous step forward as it is a major source of innovation for Research in pharma today. Read more...
